MARGINAL ZONE LYMPHOMA
Clinical trials for MARGINAL ZONE LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new MARGINAL ZONE LYMPHOMA trials appear
Sign up with your email to follow new studies for MARGINAL ZONE LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immune-boosting drug tested in untreated lymphoma patients
Disease control TerminatedThis study tested the drug pembrolizumab in 9 people with untreated B-cell non-Hodgkin lymphoma. The goal was to see if the drug helps the immune system shrink or control the cancer. The trial was stopped early, so results are limited.
Matched conditions: MARGINAL ZONE LYMPHOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 17, 2026 05:32 UTC
-
New drug combo aims to control lymphoma without chemo side effects
Disease control TerminatedThis study tested a chemotherapy-free combination of pembrolizumab and rituximab in 22 people with marginal zone lymphoma (a slow-growing blood cancer). The goal was to see if this approach could control the disease as well as standard chemo but with fewer side effects. The trial…
Matched conditions: MARGINAL ZONE LYMPHOMA
Phase: PHASE2 • Sponsor: University of Ulm • Aim: Disease control
Last updated May 13, 2026 15:58 UTC
-
Lymphoma drug combo shows promise in early trial
Disease control TerminatedThis study tested a combination of two drugs, umbralisib and rituximab, as the first treatment for people with follicular lymphoma or marginal zone lymphoma. The goal was to see how many patients had their cancer completely disappear. The study was stopped early and included 18 a…
Matched conditions: MARGINAL ZONE LYMPHOMA
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Apr 24, 2026 16:19 UTC
-
New PET dye aims to spot lymphoma more accurately, but study halted early
Diagnosis TerminatedThis study tested a new imaging agent called [68Ga]Ga-PentixaFor to see if it could detect marginal zone lymphoma better than the standard FDG PET scan. The trial planned to include many patients but was stopped early after only 8 people enrolled. The goal was to compare how well…
Matched conditions: MARGINAL ZONE LYMPHOMA
Phase: PHASE3 • Sponsor: Pentixapharm AG • Aim: Diagnosis
Last updated May 13, 2026 16:03 UTC